October 30, 2023 03:11 PM EDTUpdated October 31, 09:58 AM
Manufacturing

WuXi AppTec slash­es 2023 growth rev­enue fore­cast in half due to drop in de­mand for ear­ly-stage ser­vices

Anna Brown

News Reporter

Bio­phar­ma man­u­fac­tur­er WuXi AppTec is cut­ting its pro­ject­ed 2023 growth rev­enue from 5-7% to 2-3% af­ter re­duced busi­ness for its ear­ly-stage drug dis­cov­ery ser­vices. Specif­i­cal­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times